MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from sale ofproperty and equipment$372K Net cash provided by(used in) investing...$372K Decrease in cash, cashequivalents and restricted...-$20,581K Canceled cashflow$372K Deferred revenue$4,160K Stock-based compensation$1,154K Non-cash operating leaseexpense$859K Loss onextinguishment of debt-$378K Accounts receivable-$98K Depreciation$83K Impairment loss on propertyand equipment-$25K Net cash (used in)provided by financing...-$17,761K Net cash used inoperating activities-$3,192K Canceled cashflow$6,757K Repayment of debt$17,729K Payments under financelease obligations$32K Net loss-$7,545K Operating leaseliabilities-$976K Accounts payable-$530K Prepaid expenses andother current assets$525K Accrued expenses-$370K Other non-cash items$3K
Cash Flow
source: myfinsight.com

Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics, Inc. (MRSN)